The Pentagon says the military services must again ask troops who were forced out or who voluntarily left the military due to ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...